Ademi LLP is investigating Silk Road Medical (Nasdaq: SILK) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific.
In the transaction, Silk Road Medical shareholders will receive only $27.50 per share, reflecting an enterprise value of approximately $1.16 billion. The transaction agreement unreasonably limits competing transactions for Silk Road Medical by imposing a significant penalty if Silk Road Medical accepts a competing bid. Silk Road Medical insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Silk Road Medical’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.